ARID1A deficiency potentiates immunotherapy efficacy by elevating PD-L1 expression and TMB, impairing mismatch repair (MMR) function, and remodelling the tumor immune microenvironment (TIME) (Wang et al., 2020). This evidence concerns the gene ARID1A and neoplasm.